Mike Mason, departing president of Lilly Diabetes and Obesity
Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role
As Eli Lilly anticipates an FDA weight loss approval for its in-demand diabetes drug Mounjaro by year’s end, the drugmaker’s leader of those two areas …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
